

GLAXOSMITHKLINE PLC

Form 6-K

July 01, 2015

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of
the Securities Exchange Act of 1934

For period ending July 2015

GlaxoSmithKline plc
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address of principal executive offices)

Indicate by check mark whether the registrant files or
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F Form 40-F

--

Indicate by check mark whether the registrant by furnishing the
information contained in this Form is also thereby furnishing the
information to the Commission pursuant to Rule 12g3-2(b) under the
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc

Notification of Transactions of Directors, Persons Discharging Managerial Responsibilities or Connected Persons

I give below details of changes in the Directors' interests in the Ordinary Shares and American Depositary Shares ('ADSs') of GlaxoSmithKline plc ('Company').

On 30 June 2015, the Company's Non-Executive Directors were allocated notional Ordinary Shares at a price of £13.45 per Ordinary Share, and notional ADSs at a price of \$42.20 per ADS under the share allocation arrangements for Non-Executive Directors for the period of service from 1 April 2015 to 30 June 2015:

Non Executive Director	Ordinary Shares	No. of ADSs
Sir Philip Hampton	2,730.912	
Professor Sir Roy Anderson	673.792	
Dr Stephanie Burns		539.199
Stacey Cartwright	534.387	
Lynn Elsenhans		1,070.720
Judy Lewent		457.147
Sir Deryck Maughan		1,359.719
Dr Daniel Podolsky		1,019.789
Urs Rohner	589.536	
Hans Wijers	534.387	

The Company and the Non-Executive Directors were informed of these allocations on 1 July 2015.

This notification relates to transactions notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).

V A Whyte
Company Secretary

1 July 2015

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc
(Registrant)

Date: July 01, 2015

By: VICTORIA WHYTE

Victoria Whyte
Authorised Signatory for and on
behalf of GlaxoSmithKline plc